Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye leaves a short comment following OncoZenge’s announcement that UCLA has enrolled the first patient in its patient engagement study for BupiZenge.</li><li>We view this as an encouraging step in the company’s development strategy, providing valuable patient and clinician insights that could strengthen both the upcoming European CTA submission and future US regulatory interactions.</li></ul>

Redeye leaves a short comment following OncoZenge’s announcement that UCLA has enrolled the first patient in its patient engagement study for BupiZenge.We view this as an encouraging step in the company’s development strategy, providing valuable patient and clinician insights that could strengthen both the upcoming European CTA submission and future US regulatory interactions.

OncoZenge: UCLA engagement study enrolls first patient

Oncozenge

OncoZenge: UCLA engagement study enrolls first patient